Stifel Downgrades Neoleukin Therapeutics (NLTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Mizuho Securities Downgrades Neoleukin Therapeutics (NLTX) to Neutral
November 15, 2022 4:01 AM ESTMizuho Securities analyst Mara Goldstein downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Neutral with a price target of $2.00 (from $21.00).
For an analyst ratings summary and ratings history on Neoleukin Therapeutics click here. For more ratings news on Neoleukin Therapeutics click here.
Shares of Neoleukin Therapeutics closed at $0.53 yesterday.
... MoreGuggenheim Downgrades Neoleukin Therapeutics (NLTX) to Neutral
November 15, 2022 3:35 AM ESTGuggenheim analyst Charles Zhu downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Neoleukin Therapeutics click here. For more ratings news on Neoleukin Therapeutics click here.
Shares of Neoleukin Therapeutics closed at $0.53 yesterday.
... MoreCanaccord Genuity Downgrades Neoleukin Therapeutics (NLTX) to Hold
November 15, 2022 3:18 AM ESTCanaccord Genuity analyst William Maughan downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Hold with a price target of $1.00 (from $10.00).
For an analyst ratings summary and ratings history on Neoleukin Therapeutics click here. For more ratings news on Neoleukin Therapeutics click here.
Shares of Neoleukin Therapeutics closed at $0.53 yesterday.
... MoreNeoleukin Therapeutics (NLTX) says development of NL-201 to be discontinued for strategic reasons
November 14, 2022 4:03 PM ESTDevelopment of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of 2025 --
Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo IL-2/IL-15 agonist, and focus on advancing next-generation... More
Neoleukin Therapeutics (NLTX) Halted, News Pending
November 14, 2022 4:00 PM ESTNeoleukin Therapeutics (NASDAQ: NLTX) Halted, News Pending
